Design: Pre-treatment and post-treatment questionnaire given to patients with a diagnosis of recurrent epistaxis. Length of treatment was two months. All patients applied NoBleed as directed in the product insert as the sole treatment of their epistaxis during this period.
24 | Total Participants |
18 | Total 2nd Response |
68% | Total study Completion Rate |
79% | Percent of patients with epistaxis pre-treatment |
17 | Average number of epistaxis events per month per patient pre-treatment |
4 | Average number of epistaxis events per month per patient post-treatment |
61% | Percent of patients with complete resolution epistaxis |
28% | Percent of patients with partial resolution epistaxis |
11% | Percent of patients with no decrease in epistaxis |
94% | Percent of patients with decreased severity of epistaxis |
82% | Percent of patients with decreased duration of epistaxis episodes |
94% | Percent of patients tolerating treatment with NoBleed |
88% | Percent of patients who would recommend this product |